LB100, a Protein Phosphatase 2A Inhibitor

LB100 is a **small-molecule inhibitor of Protein Phosphatase 2A (PP2A)**, and it has garnered attention in **cancer research and therapy** due to its potential to enhance the effectiveness of chemotherapy and radiation.

🔬 What is LB100?

- **LB100** is an **experimental drug** developed by **Lixte Biotechnology**.
- It specifically targets and inhibits **Protein Phosphatase 2A (PP2A)**, a **serine/threonine phosphatase** involved in regulating numerous cellular processes such as cell growth, division, and apoptosis.

🧬 Why Inhibit PP2A?

- **PP2A** is generally considered a **tumor suppressor**, but in certain contexts, **inhibition of PP2A** can **sensitize tumor cells to chemotherapy and radiation**.
- LB100's inhibition of PP2A disrupts cancer cell signaling in a way that makes the cells **more vulnerable** to standard treatments.

🧪 Clinical Research and Trials

- **LB100** has shown **promising results in preclinical studies** and is being evaluated in **clinical trials** for:
  - **Glioblastoma**
  - **Acute myeloid leukemia (AML)**
  - **Solid tumors**
- It is often studied in **combination** with **chemotherapy** or **immune checkpoint inhibitors**, such as **anti-PD-1** therapies.

⚙️ Mechanism of Action

- By **inhibiting PP2A**, LB100 interferes with DNA damage repair pathways.

- This leads to **accumulated DNA damage in cancer cells**, making them more susceptible to:
    - **DNA-damaging agents** like radiation or doxorubicin.
    - **Checkpoint inhibitors**, enhancing the immune response.

📊 Notable Findings

- In glioblastoma models, LB100 has **enhanced the effect of temozolomide (TMZ)** and **radiation therapy**.
- It has **crossed the blood-brain barrier**, which is crucial for treating CNS cancers like glioblastoma.
- It is being evaluated in **Phase 1/2 trials** as of recent reports.

🚧 Side Effects & Considerations

- As with any PP2A inhibitor, off-target effects and systemic toxicity must be carefully evaluated.
- Clinical trials are ongoing to determine **safety**, **optimal dosage**, and **efficacy** in combination regimens.

🗒️ Summary

Feature	Details
Name	LB100
Target	Protein Phosphatase 2A (PP2A)
Developer	Lixte Biotechnology
Clinical Stage	Phase 1/2
Applications	Glioblastoma, AML, solid tumors
Mechanism	Sensitizes tumors by disrupting DNA repair

[7 Oct 2025]